Literature DB >> 17924861

Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis.

Sayeeda Rahman1, Tahminur Rahman, Aziz Al-Shafi Ismail, Abdul Rahman A Rashid.   

Abstract

The complications associated with diabetic vasculopathy are commonly grouped into two categories: microvascular and macrovascular complications. In diabetes, macrovascular disease is the commonest cause of mortality and morbidity and is responsible for high incidence of vascular diseases such as stroke, myocardial infarction and peripheral vascular diseases. Macrovascular diseases are traditionally thought of as due to underlying obstructive atherosclerotic diseases affecting major arteries. Pathological changes of major blood vessels leading to functional and structural abnormalities in diabetic vessels include endothelial dysfunction, reduced vascular compliance and atherosclerosis. Besides, advanced glycation end product formation interacts with specific receptors that lead to overexpression of a range of cytokines. Haemodynamic pathways are activated in diabetes and are possibly amplified by concomitant systemic hypertension. Apart from these, hyperglycaemia, non-enzymatic glycosylation, lipid modulation, alteration of vasculature and growth factors activation contribute to development of diabetic vasculopathy. This review focuses on pathophysiology and pathogenesis of diabetes-associated macrovasculopathy.

Entities:  

Mesh:

Year:  2007        PMID: 17924861     DOI: 10.1111/j.1463-1326.2006.00655.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  63 in total

Review 1.  The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.

Authors:  Stephen P Gray; Karin Jandeleit-Dahm
Journal:  J Mol Med (Berl)       Date:  2014-04-01       Impact factor: 4.599

2.  Calycosin entered HUVECs and ameliorated AGEs-promoted cell apoptosis via the Bcl-2 pathway.

Authors:  You-Hua Xu; Jianfeng Xiong; Shan-Shan Wang; Dan Tang; Ru-Shang Wang; Quan Zhu
Journal:  J Nat Med       Date:  2014-01       Impact factor: 2.343

3.  Diabetes-related microvascular and macrovascular diseases in the physical therapy setting.

Authors:  W Todd Cade
Journal:  Phys Ther       Date:  2008-09-18

Review 4.  Prevalence of type 2 diabetes and its complications in India and economic costs to the nation.

Authors:  R Pradeepa; V Mohan
Journal:  Eur J Clin Nutr       Date:  2017-04-19       Impact factor: 4.016

5.  Transplantation of mesenchymal cells improves peripheral limb ischemia in diabetic rats.

Authors:  Rosalinda Madonna; Stefano Delli Pizzi; Stefano Delli Pizzi; Armando Tartaro; Raffaele De Caterina
Journal:  Mol Biotechnol       Date:  2014-05       Impact factor: 2.695

6.  Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists.

Authors:  Xiaohui Du; Paul J Dransfield; Daniel C-H Lin; Simon Wong; Yingcai Wang; Zhongyu Wang; Todd Kohn; Ming Yu; Sean P Brown; Marc Vimolratana; Liusheng Zhu; An-Rong Li; Yongli Su; Xianyun Jiao; Jiwen Jim Liu; Gayathri Swaminath; Thanhvien Tran; Jian Luo; Run Zhuang; Jane Zhang; Qi Guo; Frank Li; Richard Connors; Julio C Medina; Jonathan B Houze
Journal:  ACS Med Chem Lett       Date:  2014-02-03       Impact factor: 4.345

7.  Targeting miRNA for Therapy of Juvenile and Adult Diabetic Cardiomyopathy.

Authors:  Shyam Sundar Nandi; Paras Kumar Mishra
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

8.  Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients.

Authors:  K Eeg-Olofsson; J Cederholm; P M Nilsson; B Zethelius; L Nunez; S Gudbjörnsdóttir; B Eliasson
Journal:  Diabetologia       Date:  2008-11-05       Impact factor: 10.122

9.  Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope?

Authors:  Sayeeda Rahman; Aziz Al-Shafi Ismail; Abdul Rashid A Rahman
Journal:  Int J Diabetes Dev Ctries       Date:  2009-07

10.  Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.

Authors:  James F List; Vincent Woo; Enrique Morales; Weihua Tang; Fred T Fiedorek
Journal:  Diabetes Care       Date:  2008-12-29       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.